<DOC>
	<DOCNO>NCT01013480</DOCNO>
	<brief_summary>Study 22001 , `` A Double-Blind , Placebo-Controlled , Flexible-Dose Evaluation Efficacy , Safety , Tolerability STX209 Treatment Irritability Subjects Fragile X Syndrome '' currently evaluate efficacy STX209 ( R-baclofen ) management typical problem behavior , irritability aggression , subject FXS . This study ( 22002 ) enter subject complete Study 22001 long-term , open-label study.The open-label extension protocol provide necessary data long-term safety tolerability STX209 among subject FXS receive treatment condition closely reflective general medical care .</brief_summary>
	<brief_title>An Open Label Extension Study STX209 Subjects With Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Have complete schedule visit protocol 22001 show adequately follow protocol , sufficient medical justification continue openlabel treatment STX209 , assess principal investigator Subjects medical condition might interfere conduct study , confound interpretation study result , endanger wellbeing . The occurrence continuation adverse event condition study 22001 , opinion Investigator , exclude subject participate openlabel extension .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Fragile X Syndrome</keyword>
</DOC>